Stephens & Co. Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jeff Garro maintains an Equal-Weight rating on Health Catalyst (NASDAQ:HCAT) but lowers the price target from $8 to $7.
August 08, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Stephens & Co. analyst Jeff Garro maintains an Equal-Weight rating on Health Catalyst but lowers the price target from $8 to $7.
The lowered price target from $8 to $7 by Stephens & Co. suggests a less optimistic outlook for Health Catalyst, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100